Dose escalation Phase 1b Trial of GT103 completes enrollment AND Phase 1 Expansion Cohort and Phase 2 GT103 Combination Trial with Pembrolizumab to begin in Q4 2022
Contact Us
Scott Lyman
Chief Business Officer
919-987-7190
info@gridthr.com
For Investors, Partnering and Media Information, please fill out and submit the information below: